Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_assertion type Assertion NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_head.
- NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_assertion description "[Patient proportions with TP53 defects at diagnosis or before first therapy were reported within the range 5-15 %, but they increase dramatically in pretreated cohorts (reported up to 44 %), and also in patients with Richter transformation (50 % harbor TP53 defects).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_provenance.
- NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_assertion evidence source_evidence_literature NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_provenance.
- NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_assertion SIO_000772 24014294 NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_provenance.
- NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_assertion wasDerivedFrom befree-20150227 NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_provenance.
- NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_assertion wasGeneratedBy ECO_0000203 NP753116.RAnt0kmUkJmI0nWDTAt85qBh-yDB7IOKdHipBYUgNeljI130_provenance.